| GUFIC BIOSCIENCES  Back to All Ratios | 
GUFIC BIOSCIENCES Last 5 Year Receivable days History
[Consolidated]
| Mar2025 | Mar2024 | |
|---|---|---|
| Receivable days | 106.89 | 128.09 | 
What is the latest Receivable days ratio of GUFIC BIOSCIENCES ?
| Year | Receivable days | 
|---|---|
| Mar2025 | 106.89 | 
| Mar2024 | 128.09 | 
How is Receivable days of GUFIC BIOSCIENCES Trending?
| Years | Receivable days | % Change | |
|---|---|---|---|
| Mar2025 | 106.89 | -16.55 | |
| Mar2024 | 128.09 | - | |
Other Financial Ratios of GUFIC BIOSCIENCES
| Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap | 
Compare Receivable days ratio of peers of GUFIC BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUFIC BIOSCIENCES | ₹3,338.5 Cr | -3.5% | -6.8% | -22.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹411,822.0 Cr | 1.6% | 8.2% | -8.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,811.0 Cr | -0.8% | 14.4% | 12.2% | Stock Analytics | |
| CIPLA | ₹127,688.0 Cr | -3.9% | 5.5% | 5.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,840.0 Cr | -0.5% | 1% | 7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,544.0 Cr | -2.1% | -0% | -2% | Stock Analytics | |
GUFIC BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| GUFIC BIOSCIENCES | -3.5% | -6.8% | -22.3% | 
| SENSEX | 0.7% | 4.7% | 6.1% | 
You may also like the below Video Courses
 
                     
                                     
                                     
                                    